Navigation Links
Spanish researchers sequence non-infiltrating bladder cancer exome
Date:10/19/2013

Bladder cancer represents a serious public health problem in many countries, especially in Spain, where 11,200 new cases are recorded every year, one of the highest rates in the world. The majority of these tumours have a good prognosis -- 70-80% five-year survival after diagnosis -- and they do not infiltrate the bladder muscle at the time of diagnosis -- in around 80% of cases.

Despite this, many of the tumours recur, requiring periodic cytoscopic tumour surveillance. This type of follow-up affects patients' quality of life, at the same time as incurring significant healthcare costs.

Researchers at the Spanish National Cancer Research Centre (CNIO), coordinated by Francisco X. Real, head of the Epithelial Carcinogenesis Group and Nuria Malats, head of the Genetic & Molecular Epidemiology Group, have carried out the first exome sequencing for non-infiltrating bladder cancer, the most frequent type of bladder cancer and the one with the highest risk of recurrence (the exome is the part of the genome that contains protein synthesis information).

The results reveal new genetic pathways involved in the disease, such as cellular division and DNA repair, as well as new genes -- not previously described -- that might be crucial for understanding its origin and evolution.

"We know very little about the biology of bladder cancer, which would be useful for classifying patients, predicting relapses and even preventing the illness", says Cristina Balbs, a predoctoral researcher in Real's laboratory who is the lead author of the study.

The work consisted of analysing the exome from 17 patients diagnosed with bladder cancer and subsequently validating the data via the study of a specific group of genes in 60 additional patients.

"We found up to 9 altered genes that hadn't been described before in this type of tumour, and of these we found that STAG2 was inactive in almost 40% of the least aggressive tumours", says Real.

The researcher adds that: "Some of these genes are involved in previously undescribed genetic pathways in bladder cancer, such as cell division and DNA repair; also, we confirmed and extended other genetic pathways that had previously been described in this cancer type, such as chromatin remodelling".

AN UNKNOWN AGENT IN BLADDER CANCER

The STAG2 gene has been associated with cancer just over 2 years ago, although "little is known about it, and nothing about its relationship to bladder cancer", says Balbs. Previous studies suggest it participates in chromosome separation during cell division (chromosomes contain the genetic material), which is where it might be related to cancer, although it has also been associated with maintenance of DNAs 3D structure or in gene regulation.

Contrary to what might be expected, the article reveals that tumours with an alteration in this gene frequently lack changes in the number of chromosomes, which indicates, according to Real, that "this gene participates in bladder cancer via different mechanisms than chromosome separation".

The authors have also found, by analysising tumour tissue from more than 670 patients, that alterations in STAG2 are associated, above all, with tumours from patients with a better prognosis.


'/>"/>

Contact: Nuria Noriega
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert  

Related biology technology :

1. Spanish scientists design a revolutionary data storage device
2. Spanish researchers writing in cell describe the 9 hallmarks of aging
3. Oven Releases Their 5C7-195 Temperature Controller in Spanish Speaking Locations
4. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
5. In new quantum-dot LED design, researchers turn troublesome molecules to their advantage
6. Multidisciplinary team of researchers develop world’s lightest material
7. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
8. Innovative MetaMorph® NX Software Shatters Barriers Between Researchers and Image Analysis Goals with Exclusive Visual Workflow
9. UCLA researchers demonstrate fully printed carbon nanotube transistor circuits for displays
10. Penn and Brown researchers demonstrate earthquake friction effect at the nanoscale
11. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Spanish researchers sequence non-infiltrating bladder cancer exome
(Date:2/16/2017)... BEACH, Florida , February 16, 2017 /PRNewswire/ ... improving with the infusion of innovative telemedicine application, ... monitoring services that are experiencing a boom worldwide. ... with the advancement of technologies, services and new ... Inc. (OTC: RQHTF) (TSX-V: RHT), Cellectar Biosciences, Inc. ...
(Date:2/16/2017)... 2017  Dermata Therapeutics, LLC, a biotechnology company ... variety of dermatological diseases, today announced it has ... entered into a $5 million credit facility with ... the capital for general corporate purposes to further ... treatment of serious diseases treated by dermatologists.   ...
(Date:2/16/2017)... ... February 16, 2017 , ... AxioMed announced ... professor and Harvard trained surgeon, completed the procedure on Monday, Jan. 30 at ... practicing female physician suffering from degenerative disc disease with radiculomyelopathy, as a result ...
(Date:2/16/2017)... 16, 2017  Rhythm, a biopharmaceutical company ... that result in life-threatening metabolic disorders, today ... mezzanine round of financing with existing investors ... New Enterprise Associates, Pfizer Venture Investments, Third ... investment fund. Rhythm will use the proceeds ...
Breaking Biology Technology:
(Date:1/18/2017)... Jan. 18, 2017 MedNet Solutions ... supports the entire spectrum of clinical research, is ... record-breaking year for the organization in terms of ... MedNet,s eClinical products and services. The company,s exceptional ... success of iMedNet â„¢ ...
(Date:1/12/2017)... 2017  Trovagene, Inc. (NASDAQ: TROV ), ... announced that it has signed agreements with seven strategic ... Middle East for commercialization of ... first wave of international distribution agreements for Trovagene,s CLIA ... The initial partners will introduce Trovagene,s liquid ...
(Date:1/12/2017)... PUNE, India , January 12, 2017 A new ... - 2022," projects that the global biometric technology market is expected to generate revenue ... 2022. Continue Reading ... ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
Breaking Biology News(10 mins):